SOA Wealth Advisors’s Filana Therapeutics FLNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$93 Hold
78
﹤0.01% 866
2026
Q1
$132 Hold
78
﹤0.01% 827
2025
Q4
$154 Hold
78
﹤0.01% 820
2025
Q3
$227 Hold
78
﹤0.01% 832
2025
Q2
$141 Hold
78
﹤0.01% 829
2025
Q1
$117 Hold
78
﹤0.01% 844
2024
Q4
$184 Hold
78
﹤0.01% 827
2024
Q3
$2.3K Hold
78
﹤0.01% 659
2024
Q2
$963 Hold
78
﹤0.01% 725
2024
Q1
$1.58K Hold
78
﹤0.01% 731
2023
Q4
$1.76K Hold
78
﹤0.01% 711
2023
Q3
$1.3K Hold
78
﹤0.01% 744
2023
Q2
$1.91K Hold
78
﹤0.01% 729
2023
Q1
$1.88K Sell
78
-200
-72% -$5.54K ﹤0.01% 735
2022
Q4
$8.21K Sell
278
-330
-54% -$11.9K ﹤0.01% 551
2022
Q3
$25K Buy
608
+530
+679% +$14.3K 0.01% 355
2022
Q2
$2K Hold
78
﹤0.01% 715
2022
Q1
$2K Hold
78
﹤0.01% 819
2021
Q4
$3K Sell
78
-125
-62% -$6.55K ﹤0.01% 746
2021
Q3
$12K Sell
203
-25
-11% -$2.09K ﹤0.01% 554
2021
Q2
$19K Buy
228
+150
+192% +$8.04K ﹤0.01% 471
2021
Q1
$3K Hold
78
﹤0.01% 688
2020
Q4
$3K Buy
+78
New +$696 ﹤0.01% 674

Other funds holding FLNA

SOA Wealth Advisors's FLNA Position: Q2 2026 in Review

SOA Wealth Advisors held its Filana Therapeutics (FLNA) position steady in Q2 2026 at 78 shares worth $93. The position accounts for ﹤0.01% of the portfolio, ranked #866.

SOA Wealth Advisors first reported a position in FLNA in Q4 2020 and has held it in 23 quarters since. The position peaked at $25K in Q3 2022. 15 funds tracked by Wall St. Rank hold FLNA as of Q2 2026.

  • SOA Wealth Advisors held 78 shares of Filana Therapeutics worth $93 as of Q2 2026.
  • SOA Wealth Advisors left its Filana Therapeutics share count unchanged in Q2 2026.
  • Filana Therapeutics made up ﹤0.01% of SOA Wealth Advisors's portfolio in Q2 2026, its #866 holding.
  • SOA Wealth Advisors first reported a position in Filana Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • SOA Wealth Advisors's Filana Therapeutics position peaked at $25K in Q3 2022.
  • 15 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2026.

Based on SOA Wealth Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.